Describes the initial considerations Gilead Sciences, as it is designed to deliver a strategy for AIDS drug Viread to developing countries in Africa. In October 2001, Gilead Sciences has received approval from the Food and Drug Administration United States for commercial sale Viread, a significant new drug for the treatment of HIV / AIDS. Viread was an immediate success, rapidly growing sales and market share in the U.S. in its first year on the market. Gilead as a global plan to take the drug in early 2003, a high priority was to make drugs available to millions of people in the least developed countries, where the HIV virus has been the most devastating. Pricing and distribution are key considerations. Gilead was no distribution system in place in any of these countries, and the price in the U.S. would be prohibitive in developing countries. "Hide
by David P. Baron, Keith Krehbiel, Brian Tayan Source: Stanford Graduate School of Business 10 pages. Publication Date: March 21, 2007. Prod. #: P53A-PDF-ENG
Related Case Solutions & Analyses:
Danish National Advanced Technology Foundation
JP Morgan Private Bank: Risk Management during the Financial Crisis 2008-2009
Bladelogic (A)
China and the WTO: What Price Membership
Vipp AS
Euronext.liffe and the Over-the-Counter Derivatives Market (B)
Rocky Shore Golf Links: Donald Andrews
Penny Wise Pound Foolish: Hong Kongs Penny Stock Incident
Recent Trends in Pregnancy Discrimination Law
Pain in the Hip
